Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
  1. Home
  2. Stock
  3. WOK
WOK logo

WOK Overview

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Loading chart...

High
1.170
Open
1.140
VWAP
1.12
Vol
18.68K
Mkt Cap
1.90M
Low
1.090
Amount
20.93K
EV/EBITDA(TTM)
--
Total Shares
1.72M
EV
7.03M
EV/OCF(TTM)
1.13
P/S(TTM)
0.00
Work Medical Technology Group Ltd is a holding company mainly engaged in the manufacturing of medical devices. The Company's main products include medical face masks, artery compression tourniquets, endotracheal tube holders, intubating stylets, guedel airways, and other Class I disposable medical devices, disposable breathing circuits, laryngeal mask airways, endotracheal tubes, anesthetic kit, oxygen face masks, anesthesia masks, laryngoscope blades, yankauer suction sets, nasal oxygen cannulas, and other Class II disposable medical devices, KN95 masks, filtering half mask, and other medical devices, as well as medical innovative devices and equipment, such as visualized prostatic dilatation catheter. The Company principally conducts its businesses in domestic and overseas markets, such as Asia, Africa, Europe, North America, South America, and Oceania.
Show More

Events Timeline

(ET)
2025-12-29
09:40:00
WORK Medical Technology Signs Exclusive Distribution Agreement with Shanghai Benke
select
2025-12-29
09:10:00
WORK Medical Technology Subsidiary Receives Approval for AI Blood Cell Analyzer
select
2025-12-26 (ET)
2025-12-26
20:00:00
Work Medical Technology Group Ltd Trading Halted, News Pending
select
2025-12-10 (ET)
2025-12-10
09:40:00
Work Medical Technology Group Ltd Trading Halted Due to Volatility
select
2025-12-10
09:40:00
Work Medical Technology Group Ltd Trading Resumes
select
2025-12-03 (ET)
2025-12-03
15:40:00
Work Medical Technology Group Ltd Trading Resumes
select
2025-12-03
15:30:00
Work Medical Technology Group Ltd Trading Halted Due to Volatility
select
2025-11-04 (ET)
2025-11-04
09:06:23
WORK Medical's Neologics Secures $114,000 Service Agreement
select
2025-10-21 (ET)
2025-10-21
09:06:22
WORK Medical to Invest $1 Million in Equity in Neologics Bioscience
select

News

Benzinga
9.5
02-06Benzinga
Roblox Reports Quarterly Earnings Exceeding Expectations
  • Quarterly Losses in Line: Roblox reported a quarterly loss of $0.45 per share, aligning with analyst expectations, which indicates stability in financial management despite ongoing challenges.
  • Revenue Beats Expectations: The quarterly revenue reached $2.22 billion, surpassing the analyst consensus estimate of $2.05 billion and significantly up from $1.36 billion in the same period last year, showcasing the company's success in user growth and monetization.
  • Stock Price Surge: Roblox shares jumped 14.3% to $69.24 in pre-market trading, reflecting a positive market reaction to the earnings report, which may attract more investor interest.
  • Market Dynamics Impact: The release of this earnings report could influence the stock performance of other related companies, particularly in the gaming and tech sectors, demonstrating market confidence in the industry.
Benzinga
8.5
01-02Benzinga
Intelligent Bio Solutions Plans $10 Million Private Placement, Shares Plunge 19.7%
  • Capital Raising Announcement: Intelligent Bio Solutions revealed plans to raise $10 million through a private placement, which led to a sharp 19.7% decline in its stock price during Friday's session, indicating a negative impact on investor confidence and market performance.
  • Stock Price Reaction: Following the announcement, shares of Intelligent Bio fell to $7.65, reflecting market concerns regarding the company's future financial health and potentially affecting its ability to secure further funding.
  • Market Dynamics: While Intelligent Bio's stock plummeted, other stocks such as Lavoro Limited and Ironwood Pharmaceuticals surged by 181% and 57.7% respectively, highlighting a divergence in market performance among different companies.
  • Investor Focus: The announcement of this capital raising plan may prompt investors to reassess Intelligent Bio's strategic direction, particularly in the current market environment where the necessity and timing of fundraising are critically important.
Benzinga
8.5
2025-12-31Benzinga
FuelCell Energy Files for $200 Million Stock Offering, Shares Drop 8.9%
  • Stock Offering: FuelCell Energy announced an amended sales agreement to increase the total amount of shares available for sale to $200 million, which led to an 8.9% drop in share price to $7.23 on Wednesday, indicating a negative market reaction to the dilution of shares.
  • Market Reaction: The announcement of the stock offering raised investor concerns, as the significant drop in share price could impact the company's future fundraising capabilities and market confidence, particularly in the current economic climate where investors are sensitive to equity dilution.
  • Funding Purpose: FuelCell Energy plans to use the proceeds from this offering to support its R&D and operational expenditures, and while the stock faces short-term pressure, successful fundraising could provide the necessary capital to drive technological innovation and market expansion in the long run.
  • Industry Impact: In the context of increasing competition in the hydrogen and fuel cell industry, FuelCell Energy's stock offering may affect its reputation among investors, especially as the effectiveness of its financing strategy will directly influence its market position compared to other competitors.
Benzinga
8.5
2025-12-30Benzinga
OceanFirst Financial Corp. Announces $579 Million All-Stock Acquisition of Flushing, Shares Drop 7.4%
  • Acquisition Announcement: OceanFirst Financial Corp. has announced a $579 million all-stock acquisition of Flushing Financial, which aims to enhance market share, yet the stock price fell 7.4%, indicating a negative market reaction to the deal.
  • Market Reaction: Following the acquisition news, OceanFirst's shares dropped to $18.15, reflecting investor uncertainty regarding integration risks and potential returns, which may impact the company's short-term capital flow.
  • Strategic Implications: This acquisition represents OceanFirst's strategic move to expand its presence in the New Jersey market, potentially increasing its customer base and long-term profitability, although short-term stock volatility may undermine investor confidence.
  • Investor Focus: As the acquisition progresses, the market will closely monitor how OceanFirst manages the integration process and its impact on financial performance, especially in the current economic climate where investors are cautious about the banking sector.
Benzinga
3.5
2025-12-29Benzinga
WORK Medical Secures Approval for AI Blood Cell Analyzer, Manufacturing Set for 2026
  • Product Approval: The Hunan Provincial Medical Products Administration has approved WORK Medical's AI-powered automated human blood cell morphology analyzer for manufacturing, scheduled to begin in the first half of 2026, which will enhance efficiency and accuracy in microscopic examinations, thereby strengthening the company's competitive position in the medical device market.
  • Sales Agreement Signed: The company has entered into a one-year exclusive distribution agreement with Shanghai Benke Medical Technology, establishing a minimum annual sales target of approximately $1.4 million, which will facilitate the promotion and distribution of the product in East China throughout 2026, further expanding market share.
  • Prepayment Assurance: Shanghai Benke has prepaid a performance bond of $142,300, which will be deducted from the final payment or refunded without interest upon achieving the sales target, ensuring the feasibility of the sales goal and stabilizing the company's cash flow.
  • Broad Market Prospects: CEO Shuang Wu indicated that with continuous AI algorithm iteration, the product is expected to become standard equipment in tertiary hospitals and primary-care laboratories, supporting early screening of blood disorders and quality control, while optimizing labor costs, showcasing significant market potential.
Newsfilter
7.5
2025-12-29Newsfilter
WORK Medical Signs Exclusive Agreement with Shanghai Benke, Aiming for RMB 10 Million Annual Sales
  • Exclusive Distribution Agreement: WORK Medical's subsidiary Hunan Saitumofei has signed a one-year exclusive distribution agreement with Shanghai Benke to promote the newly launched AI-Automated Blood Cell Morphology Analyzer in East China throughout 2026, which is expected to accelerate market access and drive large-scale commercialization.
  • Sales Target Establishment: Under the agreement, Hunan Saitumofei has set a minimum annual sales target of RMB 10 million, with Shanghai Benke prepaying a performance bond of RMB 1 million to ensure the achievement of this target.
  • Technological Advantage: The Analyzer has received Class II medical device manufacturing approval from Chinese regulators and utilizes high-resolution digital imaging technology, capable of processing up to 150 samples per batch with an average detection time of no more than three minutes and a classification accuracy of no less than 90%, significantly enhancing clinical testing efficiency.
  • Market Expansion Potential: By collaborating with Shanghai Benke, WORK Medical aims to leverage its established presence in the East China market to accelerate the Analyzer's market penetration, laying a solid foundation for future expansion across China and into international markets.

Valuation Metrics

The current forward P/E ratio for WORK Medical Technology Group Ltd (WOK.O) is 0.00, compared to its 5-year average forward P/E of 0.00. For a more detailed relative valuation and DCF analysis to assess WORK Medical Technology Group Ltd's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
0.00
Current PE
0.00
Overvalued PE
0.00
Undervalued PE
0.00

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.00
Undervalued EV/EBITDA
0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
0.00
Current PS
0.00
Overvalued PS
0.00
Undervalued PS
0.00

Financials

AI Analysis
Annual
Quarterly

Whales Holding WOK

Trading Trends

    Insider
    Hedge Fund
    Congress Trading

People Also Watch

Frequently Asked Questions

What is WORK Medical Technology Group Ltd (WOK) stock price today?

The current price of WOK is 1.1 USD — it has decreased -1.79

What is WORK Medical Technology Group Ltd (WOK)'s business?

Work Medical Technology Group Ltd is a holding company mainly engaged in the manufacturing of medical devices. The Company's main products include medical face masks, artery compression tourniquets, endotracheal tube holders, intubating stylets, guedel airways, and other Class I disposable medical devices, disposable breathing circuits, laryngeal mask airways, endotracheal tubes, anesthetic kit, oxygen face masks, anesthesia masks, laryngoscope blades, yankauer suction sets, nasal oxygen cannulas, and other Class II disposable medical devices, KN95 masks, filtering half mask, and other medical devices, as well as medical innovative devices and equipment, such as visualized prostatic dilatation catheter. The Company principally conducts its businesses in domestic and overseas markets, such as Asia, Africa, Europe, North America, South America, and Oceania.

What is the price predicton of WOK Stock?

Wall Street analysts forecast WOK stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for WOK is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is WORK Medical Technology Group Ltd (WOK)'s revenue for the last quarter?

WORK Medical Technology Group Ltd revenue for the last quarter amounts to NaN USD, decreased

What is WORK Medical Technology Group Ltd (WOK)'s earnings per share (EPS) for the last quarter?

WORK Medical Technology Group Ltd. EPS for the last quarter amounts to USD, decreased

How many employees does WORK Medical Technology Group Ltd (WOK). have?

WORK Medical Technology Group Ltd (WOK) has 238 emplpoyees as of March 11 2026.

What is WORK Medical Technology Group Ltd (WOK) market cap?

Today WOK has the market capitalization of 1.90M USD.